{"id":34984,"date":"2020-11-12T09:32:06","date_gmt":"2020-11-12T09:32:06","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=34984"},"modified":"2021-11-21T11:38:40","modified_gmt":"2021-11-21T11:38:40","slug":"carla-leibowitz","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/","title":{"rendered":"Carla Leibowitz"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Carla Leibowitz<\/h2>\n<h4>Chief BD Officer at Paige.AI<\/h4>\n\tCarla Leibowitz is Chief Business Development Officer at Paige, where she leads partnership teams across verticals as well as marketing and product strategy. Prior to joining the company, she led corporate development and strategy at Arterys, the first company to achieve FDA clearances for several products that combine cloud computing and artificial intelligence.\nAs Chief Business Development Officer at Paige, Carla&#8217;s role encompasses ecosystem development, evidence generation and market strategy. Over this role and previous roles, including Business Lead of healthcare AI research partnerships at NVIDIA and head of Corporate Development and Strategy at Arterys, Carla has successfully crafted partnerships at the intersection of AI and healthcare, bringing together technologists, clinicians and product experts to build and study AI-based products in the healthcare space. Carla has an MBA from the Stanford Graduate School of Business and engineering degrees from both MIT and Stanford.\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2.jpeg\" alt=\"Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,&lt;svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/&gt;\" data-srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-201x300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-686x1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-768x1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-630x940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-420x627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-315x470.jpeg 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Biomarkers in pathology and radiology\n\t<\/h3>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/paige.ai\/\" target=\"_blank\" rel=\"noopener\">https:\/\/paige.ai\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/carla-leibowitz-b13551\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Carla Leibowitz Chief BD Officer at Paige.AI Carla Leibowitz is Chief Business Development Officer at Paige, where she leads partnership teams across verticals as well as marketing and product strategy. Prior to joining the company, she led corporate development and strategy at Arterys, the first company to achieve FDA clearances for several products that combine&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33361,"parent":34845,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-34984","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Carla Leibowitz &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Carla Leibowitz is Chief BD Officer at Paige.AI. Prior, she led Corporate Development and Strategy at Arterys, the first company to achieve FDA clearances for several products that combine cloud computing and artificial intelligence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Carla Leibowitz &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Carla Leibowitz is Chief BD Officer at Paige.AI. Prior, she led Corporate Development and Strategy at Arterys, the first company to achieve FDA clearances for several products that combine cloud computing and artificial intelligence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-21T11:38:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/\",\"name\":\"Carla Leibowitz &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg\",\"datePublished\":\"2020-11-12T09:32:06+00:00\",\"dateModified\":\"2021-11-21T11:38:40+00:00\",\"description\":\"Carla Leibowitz is Chief BD Officer at Paige.AI. Prior, she led Corporate Development and Strategy at Arterys, the first company to achieve FDA clearances for several products that combine cloud computing and artificial intelligence.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CDx\/Biomarkers &#038; Biobanking 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Carla Leibowitz\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Carla Leibowitz &#8226; BioTech Pharma Summit","description":"Carla Leibowitz is Chief BD Officer at Paige.AI. Prior, she led Corporate Development and Strategy at Arterys, the first company to achieve FDA clearances for several products that combine cloud computing and artificial intelligence.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/","og_locale":"en_US","og_type":"article","og_title":"Carla Leibowitz &#8226; BioTech Pharma Summit","og_description":"Carla Leibowitz is Chief BD Officer at Paige.AI. Prior, she led Corporate Development and Strategy at Arterys, the first company to achieve FDA clearances for several products that combine cloud computing and artificial intelligence.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-11-21T11:38:40+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/","name":"Carla Leibowitz &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg","datePublished":"2020-11-12T09:32:06+00:00","dateModified":"2021-11-21T11:38:40+00:00","description":"Carla Leibowitz is Chief BD Officer at Paige.AI. Prior, she led Corporate Development and Strategy at Arterys, the first company to achieve FDA clearances for several products that combine cloud computing and artificial intelligence.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/carla-leibowitz\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"CDx\/Biomarkers &#038; Biobanking 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/"},{"@type":"ListItem","position":3,"name":"Carla Leibowitz"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=34984"}],"version-history":[{"count":6,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34984\/revisions"}],"predecessor-version":[{"id":37120,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34984\/revisions\/37120"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34845"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33361"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=34984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}